Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial "DASH"

Not yet recruiting

Phase 1/2 Results N/A

Summary of Purpose

Aneurysmal subarachnoid hemorrhage (SAH) is a form of stroke in which secondary neurological deterioration is an important cause of mortality and morbidity. These secondary changes, so called delayed cerebral ischemia (DCI), are caused by lysis of erythrocytes which can react to form iron, an toxic substance to the brain. Iron chelators remove the excess of iron and are standard care in iron-overloaded patients....

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 September 2017.

1 Dec 2017 20 Jul 2016 1 Dec 2017 1 Jun 2018 1 Sep 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment